QUVIVIQ

Class [005]
Pharmaceutical preparations for the prevention or treatment of inflammatory diseases and inflammatory autoimmune disorders, namely chronic rhinosinusitis, asthma, chronic obstructive pulmonary disorder, atherosclerosis, myocarditis, sarcoidosis, inflammatory demyelinating diseases, multiple sclerosis, Guillain Barré syndrome, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, lupus nephritis, and auto-immune encephalomyelitis; pharmaceutical preparations for the prevention or treatment of neurodegenerative diseases and disorders, namely Alzheimer's disease, Lewy body dementia, Parkinson's disease, vascular dementia, subcortical dementia, frontotemporal dementia, multi-infarct dementia, arteriosclerotic dementia, and Huntington's disease; pharmaceutical preparations for the prevention or treatment of neuropsychiatric symptoms in dementia, namely agitation associated with dementia, aggression associated with dementia, confusion associated with dementia, and sundown syndrome; pharmaceutical preparations for the prevention or treatment of sleep disorders, namely dyssomnias, parasomnias, insomnias, primary insomnia, idiopathic insomnia, chronic insomnia, situational transient insomnias, insomnias associated with depressive disorders, epilepsy, autism spectrum disorders, attention deficit hyperactivity disorder (ADHD), or Alzheimer's disease, sleep apnea syndrome, periodic limb movement disorder, restless leg syndrome, circadian rhythm sleep disorders, time-zone-change syndrome, REM sleep interruptions, nightmare disorder, sleep terror disorder, and sleepwalking disorder; pharmaceutical preparations for the prevention or treatment of physical and psychological addictions, namely gambling addictions, internet addictions, eating addictions, nicotine addictions, and drug addictions; pharmaceutical preparations for the prevention or treatment of anxieties, namely generalized anxiety disorders (GAD), obsessive compulsive disorders (OCDs), acute stress disorders, posttraumatic stress disorders (PTSDs), panic anxiety disorders (PADs), avoidance, and somatoform disorders; pharmaceutical preparations for the prevention or treatment of metabolic disorders, namely polydipsias, anorexias, compulsive eating disorders, obesity, bulimias, cachexia, and binge eating disorder; pharmaceutical preparations for the prevention or treatment of mood disorders, namely depressive disorders, major depressive episode, manic episode, mixed episode and hypomanic episode, dysthymic disorders, bipolar disorders, and cyclothymic disorder; pharmaceutical preparations for the prevention or treatment of epilepsy; pharmaceutical preparations for the prevention or treatment of pain, namely neuropathic pain; pharmaceutical preparations for the prevention or treatment of cerebrovascular accident, and stroke; pharmaceutical preparations for the prevention or treatment of nausea.